Michelle Carr, Author at BioTuesdays

Developments

Medicus provides update on Phase 2 study of D-MNA in BCC

Medicus Pharma (NASDAQ:MDCX) announced that its SKNJCT-003 Phase 2 study, evaluating the efficacy of two dose levels of D-MNA for the treatment of nodular basal cell carcinoma (BCC), has now randomized more than 50% of...

February 14, 2025

Developments

Top-tier journal describes unique properties of Aclaris’ ATI-2138

Aclaris Therapeutics (NASDAQ:ACRS) has announced that a publication in The Journal of Pharmacology and Experimental Therapeutics describes the unique properties its investigational drug, ATI-2138, which is in...

February 12, 2025

Developments

OIO grants HEALWELL regulatory approval to acquire Orion Health

HEALWELL AI (TSX:AIDX; QTCQX:HWAIF) has announced that New Zealand’s Overseas Investment Office (OIO) has granted consent for the company to acquire all ordinary shares of Orion Health, based in Auckland, New Zealand...

February 10, 2025

Developments

Ekso Bionics names National Seating & Mobility as exclusive distributor of Ekso Indego Personal device within the complex rehabilitation technology industry

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) has named National Seating & Mobility (NSM), a leading provider of complex rehabilitation technology (CRT), mobility and accessibility solutions, as the exclusive Ekso...

February 10, 2025

Developments

New data from BioRestorative Therapies’ ongoing Phase 2 trial of cell-based BRTX-100 in cLDD potentially show disc microenvironment remodeling in addition to reported improvements in VAS and ODI

BioRestorative Therapies (NASDAQ:BRTX) presented new preliminary 26–52 week blinded data from the first 15 patients with chronic lumbar disc disease (cLDD) enrolled in the ongoing Phase 2 clinical trial of BRTX-100. The...

February 10, 2025

Developments

Stereotaxis receives CE Mark for cardiac ablation catheter

Stereotaxis (NYSE:STXS) has announced that it has received European CE Mark approval for its MAGIC ablation catheter, designed to perform cardiac ablation procedures aimed at treating heart arrhythmia. According to...

January 27, 2025

Developments

Veru reports positive topline results of Phase 2b study of enobosarm for weight loss

Veru (NASDAQ:VERU) has announced positive topline results from its Phase 2b QUALITY clinical study evaluating the safety and efficacy of enobosarm in patients receiving WEGOVY (semaglutide) for weight reduction...

January 27, 2025

Developments

Social Capital’s Chamath Palihapitiya calls out Perimeter’s AI-driven cancer margin visualization technology on X show

Chamath Palihapitiya Renowned Silicon Valley venture capitalist, entrepreneur, and former Facebook executive, Chamath Palihapitiya, sat down with Tucker Carlson today to talk about several topics, including AI’s...

January 24, 2025

Executive Moves

Biodexa names Dr. Gary A. Shangold as CMO

Biodexa Pharmaceuticals (NASDAQ:BDRX) has announced the appointment of Dr. Gary A. Shangold as chief medical officer (CMO), effective immediately. The company stated that Dr. Shangold brings extensive experience across...

January 22, 2025

Developments

Evaxion completes dosing of personalized vaccine for advanced melanoma

Evaxion Biotech (NSADAQ:EVAX) has announced the completion of dosing for 16 patients in a Phase 2 trial of its lead asset, EVX-01, a personalized cancer vaccine under development for advanced melanoma. According to...

January 16, 2025

Author - Michelle Carr

Medicus provides update on Phase 2 study of D-MNA in BCC

Top-tier journal describes unique properties of Aclaris’ ATI-2138

OIO grants HEALWELL regulatory approval to acquire Orion Health

Ekso Bionics names National Seating & Mobility as exclusive distributor of Ekso Indego Personal device within the complex rehabilitation technology industry

New data from BioRestorative Therapies’ ongoing Phase 2 trial of cell-based BRTX-100 in cLDD potentially show disc microenvironment remodeling in addition to reported improvements in VAS and ODI

Stereotaxis receives CE Mark for cardiac ablation catheter

Veru reports positive topline results of Phase 2b study of enobosarm for weight loss

Social Capital’s Chamath Palihapitiya calls out Perimeter’s AI-driven cancer margin visualization technology on X show

Biodexa names Dr. Gary A. Shangold as CMO

Evaxion completes dosing of personalized vaccine for advanced melanoma

Subscribe